Testing Brain Stimulation to Study Movement Intention in Psychogenic Movement Disorders
Tests brain stimulation methods to study movement intention in adults with seizures or movement disorders.
Plain-language title generated from the registry record
Registry title: Modulating Movement Intention Via Cortical Stimulation
Key facts
- Where
- New York, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT03233399, who can take part
Where in United States
- New York University School of MedicineNew York, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- NYU Langone Health
- Trial code
- NCT03233399
- Record updated
- 25 September 2026
- Original description
The purpose of this protocol is to learn about movement intention and volition. To improve such knowledge, investigators will conduct sub-studies using multiple non-invasive methodologies. These results could provide preliminary data for subsequent studies evaluating local and global efficacy of plasticity-inducing treatments for PMD symptoms.Read full original descriptionShow less
Modulating Movement Intention Via Cortical Stimulation in Healthy Subjects and Patients With Psychogenic Movement Disorders and Non-epileptic Seizures
The purpose of this protocol is to learn about movement intention and volition. To improve such knowledge, investigators will conduct sub-studies using multiple non-invasive methodologies. These results could provide preliminary data for subsequent studies evaluating local and global efficacy of plasticity-inducing treatments for PMD symptoms.
Inclusion: (Healthy Controls); Fluent in English; (Patients with PMD or PNES):; Diagnosis of PMD/PNES confirmed by a neurologist with expertise in movement disorders; Per the treating neurologist, subject is unlikely to require treatment and/or dosage changes for 3-6 months following screening.
Exclusion: Taking tricyclic antidepressant or antiepileptic medications or CNS active drugs under "strong potential hazard" list in Rossi et al., 2009; Taking tricyclic antidepressant medications or CNS active drugs under "strong potential hazard" list in Rossi et al., 2009; Any history of a significant neurological disorder, which may interfere with the interpretation of study data, as determined by the PI; Chronic or progressive medical condition; Any history of traumatic brain injury or significant head trauma; History of any psychotic disorder or other psychiatric condition which may interfere with data interpretation; Current diagnosis of any inflammatory or autoimmune disorder within last 6 months; PMD and PNES Patients; Any history of traumatic brain injury or significant head trauma; Diagnosis of organic seizure disorder, including febrile seizures and tonic-clonic seizures; Neurological disorder other than PMD and PNES including stroke, fainting spells or syncope of unknown cause(s); Major or unstable medical illness, especially any current diagnosis of inflammatory or autoimmune disorders within last 6 months; Diagnosis of dementia, or Montreal Cognitive Assessment (MoCA) ≤24; History of significant uncontrollable movements of the head; Currently meets criteria for substance abuse or dependence; Pregnancy; Metal or devices in the head, including neurostimulators or metal foreign bodies; Any other implanted metal device, including pacemaker, spinal cord stimulator, VNS; Any other ferromagnetic substance in the body that may increase study risk (including dental prosthetics, etc.); Metal or devices in the head, including neurostimulators or metal foreign bodies; Recurrent visual hallucinations, within the past 6 months; Any clinically significant abnormality on vital signs.